ライフサイエンスコーパス: HBIG

1 HBIG and lamivudine combination therapy was administered

2 HBIG mono-therapy was administered to one patient.

3 HBIG was given perioperatively and continued thereafter;

4 observed in 1 (3.6%) patient at 33 mo after HBIG discontinuation, which became negative after a sing

5 , although careful follow-up is needed after HBIG discontinuation, whereas further larger studies are

6 Among HBIG recipients, the HBsAg-positive rate was significant

7 nts of HBsAg-positive women receive HepB and HBIG </=12 hours of birth.

8 HepB and HBIG are administered at birth to infants of HBsAg-posit

9 Lamivudine and HBIG combination decreases HBV recurrence 4-fold.

10 combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver tr

11 n liver transplantation (LT) recipients, but HBIG is costly and inconvenient to administer, prompting

12 ed or selected by immune pressure exerted by HBIG.

13 who developed recurrent hepatitis B despite HBIG prophylaxis were compared.

14 who developed recurrent hepatitis B despite HBIG prophylaxis, and to determine if these mutations ca

15 nsplantation), it is possible to discontinue HBIG and maintain only long-term nucleos(t)ide analogue(

16 The combination of lamivudine and high-dose HBIG can protect against reinfection of the hepatic allo

17 ion with the use of lamivudine and high-dose HBIG.

18 fficacy of a short, fixed scheme of low-dose HBIG plus NA followed by long-term NA monoprophylaxis ag

19 patient received a fixed scheme of low-dose HBIG plus NA for 6 mo post-LT and then continued with lo

20 ificant problem with monotherapy with either HBIG or lamivudine.

21 -negative mothers who were or were not given HBIG.

22 HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days and monthly for 6

23 combination of hepatitis B immune globulin (HBIG) and high-barrier nucleos(t)ide analogues (NUCs) is

24 al and low-dose hepatitis B Immune globulin (HBIG) can effectively prevent HBV recurrence in greater

25 Hepatitis B immune globulin (HBIG) dosing regimens have been poorly defined, utilize

26 Hepatitis B immune globulin (HBIG) has been an integral component of prophylaxis agai

27 Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) r

28 ose intravenous hepatitis B immune globulin (HBIG) treatment with continued lamivudine treatment.

29 unotherapy with hepatitis B immune globulin (HBIG).

30 In this group, HBIG-free prophylaxis cannot be recommended.

31 on and dosage of hepatitis B immunoglobulin (HBIG) administration, particularly in patients transplan

32 the second case, hepatitis B immunoglobulin (HBIG) immunoprophylaxis was administered in an attempt t

33 rate, even with hepatitis B immunoglobulin (HBIG) prophylaxis.

34 d lamivudine and hepatitis B immunoglobulin (HBIG) significantly reduced the reinfection rate (P<0.03

35 nd administering hepatitis B immunoglobulin (HBIG) to newborns.

36 ovir, lamivudine+hepatitis B immunoglobulin (HBIG), or lamivudine+entecavir on direct sequencing were

37 infants receive hepatitis B immunoglobulin (HBIG).

38 -positive rate was 15% in HB immunoglobulin (HBIG) recipients (adjusted odds ratio [OR]: 15.63; 95% c

39 eceived hepatitis B-specific immunoglobulin (HBIG) at birth.

40 The efficacy of combination lamivudine/HBIG prophylaxis has not been reported.

41 .796; P=0.020) and combination of lamivudine/HBIG (RR, 0.249; P=0.021) are independently associated w

42 igen (HBeAG)-positive patients required more HBIG to achieve these goals than HBeAG-negative individu

43 Administration of HBIG to infants born to HBeAg-negative mothers did not a

44 s B DNA levels did not predict the amount of HBIG required.

45 rence post-LT but concerns about the cost of HBIG and access to high-barrier NUCs have led to a reduc

46 We conclude that a very short course of HBIG combined with long-term antiviral therapy is highly

47 n high-risk patients, and discontinuation of HBIG in favor of alternative prophylaxis strategies lack

48 which became negative after a single dose of HBIG 1000 IU/L, whereas both serum HBV DNA and HDV RNA r

49 reduction in the use, dose, and duration of HBIG in recent years.

50 e 'a' determinant region and the duration of HBIG therapy.

51 After 6 months, 1000 IU of HBIG was given IM. every 2 weeks for 18 months.

52 provides an updated analysis of the role of HBIG in preventing HBV recurrence post-LT, alongside a d

53 ese mutations can revert after withdrawal of HBIG.

54 had a de novo change after the withdrawal of HBIG.

55 bined with a short course (in hospital only) HBIG in liver transplant recipients with HBV DNA less th

56 ed in 1 of 1050 children who did not receive HBIG (.095%).

57 Two control patients who did not receive HBIG had no change in the 'a' determinant in their postt

58 Among students who did not receive HBIG, there was a significantly negative association bet

59 ho did not were more likely to have received HBIG at birth, suggesting that passive antibody may inte

60 V DNA undetectable to 100 IU/mL who received HBIG 5000 IU in anhepatic phase and daily for 5 days tog

61 The single patient who received HBIG monotherapy became HbsAg+ at 6 months.

62 antigen (HBeAg) positivity and who received HBIG off-schedule.

63 in liver transplant recipients who received HBIG prophylaxis.

64 Short-term HBIG prophylaxis reduced costs by 11.1%, while lifetime

65 The cost analysis showed that HBIG contributes approximately 12.4% (euro 49,000) to th

66 usion, despite advancements in NUCs therapy, HBIG remains a cornerstone of HBV prophylaxis post-LT, p

67 In addition to HBV vaccines, HBIG was given to all 583 children with hepatitis B e an

68 antigen (HBsAg)-positive mothers and whether HBIG administration reduces transmission.

69 patients receiving combination therapy with HBIG and lamivudine have remained HbsAg-.

70 Combination therapy with HBIG and lamivudine may prevent de novo HBV infection in

71 the nucleoside analogue lamivudine, without HBIG, in patients undergoing liver transplantation.